Pharmaceutical company
Appears in 6 stories
Invented the four new antibodies; leads research and development
Sanofi's biggest product is running out of room. Dupixent, the anti-inflammation antibody it co-developed with Regeneron, brought in $17.8 billion in 2025—roughly 36% of the French company's sales—and a key US patent expires in 2031.
Updated Oct 3
Otarmeni approved by FDA in April 2026; provided free to eligible US patients
A single injection into the inner ear can now restore hearing in children born deaf. In April 2026 the FDA approved Otarmeni, the first gene therapy for inherited hearing loss, after about 80% of 24 trial participants gained measurable hearing and 42% could pick up whispers.
Holds exclusive olatorepatide rights outside Greater China; planning global registrational program
Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.
Updated Oct 2
Maker of Eylea, the comparator in the DAYBREAK trial
A drug Kodiak Sciences shelved in 2023 after a cataract safety signal is now on track for an FDA filing. The company reported Monday that both its experimental therapies for wet age-related macular degeneration met their primary endpoints against Regeneron's standard-of-care Eylea in the Phase 3 DAYBREAK trial.
Updated Sep 29
Co-development and royalty partner on lonvo-z
On April 27, 2026, Intellia Therapeutics reported results from Phase 3 testing of lonvoguran ziclumeran (lonvo-z), a one-time in-body CRISPR gene-editing therapy for hereditary angioedema. The 80-patient randomized double-blind trial found a single IV infusion cut debilitating swelling attack rates by 87% versus placebo (weeks 5-28); 62% of patients became attack-free and stopped all preventive medications. The safety profile was clean: no serious adverse events, and infusion-related reactions, headache, and fatigue—the most common complaints—were mild or moderate.
Updated May 31
Co-developer and co-marketer of Dupixent; 74% of revenue dependent on key biologic drugs
Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
